Preferred Label : AXL Inhibitor SLC-391;
NCIt definition : An orally bioavailable and selective inhibitor of the receptor tyrosine kinase AXL
(UFO), with potential immunostimulating and antineoplastic activities. Upon oral administration,
SLC-391 targets, binds to and prevents the activation of AXL. This blocks AXL-mediated
signal transduction pathways, and inhibits both AXL-mediated tumor cell growth, proliferation
and migration and AXL-mediated immunosuppression. AXL, a member of the Tyro3, AXL
and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor
cell types and also expressed in a variety of immune cells including macrophages,
natural killer (NK) cells, and regulatory T-cells (Tregs). It plays a key role in
tumor cell proliferation, survival, invasion and metastasis, and is a mediator of
immunosuppression. Its expression is associated with drug resistance and poor prognosis.;
Molecule name : SLC 391; SLC-391; XZB 0004; XZB-0004;
NCI Metathesaurus CUI : CL1407197;
Origin ID : C173362;
UMLS CUI : C5417961;
Semantic type(s)
- concept_is_in_subset
- has_target
